# Hepatitis C: State of Medicaid Access Report Card

## District of Columbia



| Grade | Recommendations to Improve Patient Access |
|---|---|
| A+ | • Continue to ensure broad access to HCV treatment. |

### State Overview

As of July 2026, 237,183 individuals were enrolled in Medicaid and CHIP in the District of Columbia (DC).[1] DC Medicaid contracts with two managed care organizations (MCOs): AmeriHealth Caritas DC and MedStar Family Choice DC.[2] In a federal analysis of 2023-2024 Medicaid claims data, only 26% of DC adult Medicaid beneficiaries newly identified with HCV received timely HCV treatment.[3]

The District of Columbia Preferred Drug List designates Mavyret, sofosbuvir/velpatasvir, and Vosevi as preferred HCV treatment regimens.[4]

| Deductions | | Policy |
|---|---|---|
| Prior Authorization | | Prior authorization is not required for preferred HCV treatment regimens.[5] |
| Fibrosis Restrictions | | DC Medicaid does not impose fibrosis restrictions.[6] |
| Substance Use Restrictions | | DC Medicaid does not appear to impose substance use restrictions.[7] |
| Prescriber Restrictions | | DC Medicaid does not impose prescriber restrictions. [8] |
| Retreatment Restrictions | | DC Medicaid does not impose retreatment restrictions.[9] |
| Access in Managed Care | | Both MCOs (AmeriHealth Caritas DC[10] and Medstar Family Choice[11]) impose the same requirements as FFS, though Medstar's PDL only includes sofosbuvir/velpatasvir as a preferred regimen. |
| Additional Restrictions | | DC Medicaid does not appear to impose additional restrictions for preferred regimens.[12] |
| **Total Deductions** 0 | **Total Score [100-Deductions]** 100 | **Grade** A+ |

### Contact Your State Officials

**Medicaid Office:[13] Melisa Byrd, Medicaid Director, Department of Health Care Finance, District of Columbia**
One Judiciary Square 441 4th Street, N.W., Washington, DC 20001; Telephone: (202) 442-9075; Email: melisa.byrd@dc.gov

**Pharmacy & Therapeutics Committee:[14] Charlene Fairfax, RPh, Senior Pharmacist, Department of Health Care Finance**
441 Fourth Street NW, Suite 900, Washington, DC 20001; Telephone: (202) 442-9076; Email: charlene.fairfax@dc.gov

### Key Sources

**Preferred Drug List**: DC Department of Health Care Finance, Preferred Drug List (Sep. 18, 2026).
**Clinical Criteria**: DC Department of Health Care Finance, Revision of Hepatitis C Treatment Coverage Policy (August 24, 2022).

[1] Centers for Medicare & Medicaid Services, Medicaid & CHIP in District of Columbia, https://www.medicaid.gov/state-overviews/stateprofile.html?state=district-of-columbia.
[2] Medicaid Managed Care Plans (MCPs), https://dhcf.dc.gov/page/medicaid-managed-care-plans-mcps.
[3] U.S. Department of Health and Human Services, Office of Inspector General. *Less Than 25 Percent of Medicaid Beneficiaries With Hepatitis C Received Treatment Within 6 Months.* Data Brief OEI-BL-24-00450 (Nov. 2, 2026), https://perma.cc/PDA7-HQUM.
[4] Preferred Drug List.
[5] Clinical Criteria.
[6] Clinical Criteria.
[7] Clinical Criteria.
[8] Clinical Criteria.
[9] Clinical Criteria.
[10] AmeriHealth Caritas District of Columbia, Medicaid Drug Formulary (June 11, 2026), https://www.amerihealthcaritasdc.com/content/dam/amerihealth-caritas/acdc/pdf/member/drug-formulary.pdf.coredownload.inline.pdf.
[11] Medstar Family Choice, Medicaid Drug Formulary (effective Oct. 1, 2026), https://www.medstarfamilychoicedc.com/-/media/project/mho/mfcdc/pharmacy-materials/508_medstar-family-choice-of-dc-formulary-effective-1012026.pdf.
[12] Clinical Criteria.
[13] National Association of Medicaid Directors, Who We Are, https://medicaiddirectors.org/who-we-are/medicaid-directors/.
[14] District of Columbia Department of Health Care Finance, Contact Us, https://dc-pbm.com/provider-contact-us.